<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615144</url>
  </required_header>
  <id_info>
    <org_study_id>17-596</org_study_id>
    <nct_id>NCT03615144</nct_id>
  </id_info>
  <brief_title>TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors</brief_title>
  <official_title>A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if removing a specific type of white blood cell
      (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve
      results of blood stem cell transplant for the participant's disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>For this trial, patients will be assigned to receive one of two conditioning regimens, based on their disease, disease severity, organ status and history of red blood cell alloimmunization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-Malignant Hematologic Disorders</condition>
  <arm_group>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 70 mg/m2/day x 2</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Thiotepa 7.5 mg/kg/day x 2</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Clofarabine 20-30 mg/m2/day x 5</description>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2/day x 5</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)</intervention_name>
    <description>antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CliniMACS reagents</intervention_name>
    <description>Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.</description>
    <arm_group_label>Melphalan/Thiotepa/ Fludarabine</arm_group_label>
    <arm_group_label>Melphalan/Thiotepa/Clofarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Inclusion Criteria:

          -  Lethal disorders of Hematopoiesis correctable by transplant for which Alpha βeta
             T-cell and CD-19 depleted allogeneic hematopoietic stem cell transplantation is
             indicated including:

          -  Sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+, HbSD, HbSE) with at least
             one of the following criteria (Walters et al):

               1. Cerebrovascular accident lasting longer than 24 hours

               2. Impaired neuropsychological function with abnormal brain MRI/MRA

               3. Recurrent hospitalizations (&gt;2 episodes/year over several years) or exchange
                  transfusions for acute chest syndrome

               4. Recurrent priapism

               5. Stage I or II sickle chronic lung disease

               6. Sickle cell nephropathy (moderate to severe proteinuria or glomerular filtration
                  rate 30-50% of predicted normal value for age)

               7. Bilateral proliferative retinopathy with major visual impairment in at least one
                  eye

               8. Osteonecrosis of multiple joints

               9. Red cell alloimmunization during chronic transfusion therapy

          -  Thalassemia major with at least one of the following criteria:

               1. Age &lt;16 years

               2. Available HLA-identical sibling

               3. Red blood cell transfusion dependency

               4. Lucarelli class 1 or 2 risk status (i.e. with only 0-2 of the following factors:
                  hepatomegaly, portal fibrosis, or poor response to chelation therapy)

               5. Recurrence of disease after previous stem cell transplant

          -  Bone Marrow Failure Syndromes:

               1. Aplastic anemia refractory to immunosuppressive therapy

               2. Diamond Blackfan Anemia refractory to conventional therapy

               3. Shwachman-Diamond Syndrome

               4. Severe Congenital Neutropenia

               5. Congenital Amegakaryocytic Thrombocytopenia

               6. Thrombocytopenia Absent Radii syndrome

               7. Other marrow failure disorders not otherwise specified

          -  Autoimmune cytopenias refractory to all conventional treatments

               1. Autoimmune hemolytic anemia

               2. Immune thrombocytopenia

               3. Evan's syndrome

               4. Pure red cell aplasia

          -  Histiocytic disorders:

               1. Hemophagocytic lymphohistiocytosis

               2. High risk, recurrent or refractory Langerhans cell histiocytosis

               3. Secondary HLH

        Subject Inclusion Criteria:

          -  Recipient's age birth to &lt; 70 years old

          -  Patients must have adequate organ function measured by:

          -  Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 50% and must
             improve with exercise.

          -  Hepatic: &lt; 3x ULN AST and ≤ 1.5 mg/dl total serum bilirubin, unless there is
             congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused
             by the disease in which the patient is receiving a transplant for. Patients with
             higher bilirubin levels due to causes other than active liver disease are also
             eligible with PI approval e.g. patients with PNH, Gilbert‟s disease or other hemolytic
             disorders.

          -  Pulmonary: asymptomatic or if symptomatic, DLCO ≥ 50% of predicted (corrected for
             hemoglobin).

          -  Renal: serum creatinine ≤1.5x normal for age. If serum creatinine is outside the
             normal range, then CrCl &gt; 70 mL/min/1.73m2 (calculated or estimated) or GFR
             (mL/min/1.72m2) &gt;30% of predicted normal for age.

          -  Normal GFR in Children and Young Adults.

        Donor Inclusion Criteria:

          -  Each donor must meet criteria outlined by institutional guidelines and be medically
             eligible to donate according to NMDP (or equivalent donor search organization)
             criteria including testing for antibodies to Human TLymphotrophic Virus Types I &amp; II
             (Anti-HTLV-I/II) and screening for West Nile Virus, Creutzfeldt-Jakob disease and
             Zika.

          -  Pediatric donors should weigh ≥ 25.0 kg, have adequate peripheral venous catheter
             access for leukapheresis or must agree to placement of a central catheter.

          -  Donor should be healthy and agree to receive G-CSF followed by donation of peripheral
             blood stem cells.

          -  Donors must agree to anesthesia and marrow donation (in cases of inadequate PBSC
             collection).

          -  Related or unrelated donors who are 7/8 or 8/8 HLA-antigen matched for haplotypes A,
             B, C, DRB1 OR Related donors who are 4-6/8 HLA-antigen matched.

        Subject Exclusion Criteria:

          -  Female patients who are pregnant or breast-feeding

          -  Active viral, bacterial or fungal infection

          -  Patient seropositive for HIV-I/II; HTLV-I/II

          -  Karnofsky (adult)/Lansky (pediatric) &lt; 70%

          -  Inherited DNA repair deficiency: Fanconi Anemia and Dyskeratosis Congenita. These are
             presently undergoing transplantation based on a multi-center protocol

          -  Patients with Thalassemia major with Pesaro risk score &gt;II

          -  Inherited metabolic disorders: Hurler Syndrome, Sly syndrome (MPSVIII),
             α-Mannosidosis, X- ALD, Osteopetrosis

        Donor Exclusion Criteria:

          -  Donors who are seropositive for HIV-I/II or HTLV-I/II and female patients who are
             pregnant or breastfeeding will not be eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Cancio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Cancio, MD</last_name>
    <phone>212-639-2446</phone>
    <email>canciom@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Farid Boulad, MD</last_name>
    <phone>212-639-6684</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial SloanKettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cancio, MD</last_name>
      <phone>212-639-2446</phone>
    </contact>
    <contact_backup>
      <last_name>Farid Boulad, MD</last_name>
      <phone>212-639-6684</phone>
    </contact_backup>
    <investigator>
      <last_name>Maria Cancio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-cell</keyword>
  <keyword>B-cell</keyword>
  <keyword>CliniMACS System</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Thiotepa</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>17-596</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

